Rv0180c contributes to Mycobacterium tuberculosis cell shape and to infectivity in mice and macrophages.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
11 2021
Historique:
received: 29 03 2021
accepted: 08 10 2021
revised: 11 11 2021
pubmed: 2 11 2021
medline: 15 12 2021
entrez: 1 11 2021
Statut: epublish

Résumé

Mycobacterium tuberculosis, the main causative agent of human tuberculosis, is transmitted from person to person via small droplets containing very few bacteria. Optimizing the chance to seed in the lungs is therefore a major adaptation to favor survival and dissemination in the human population. Here we used TnSeq to identify genes important for the early events leading to bacterial seeding in the lungs. Beside several genes encoding known virulence factors, we found three new candidates not previously described: rv0180c, rv1779c and rv1592c. We focused on the gene, rv0180c, of unknown function. First, we found that deletion of rv0180c in M. tuberculosis substantially reduced the initiation of infection in the lungs of mice. Next, we established that Rv0180c enhances entry into macrophages through the use of complement-receptor 3 (CR3), a major phagocytic receptor for M. tuberculosis. Silencing CR3 or blocking the CR3 lectin site abolished the difference in entry between the wild-type parental strain and the Δrv0180c::km mutant. However, we detected no difference in the production of both CR3-known carbohydrate ligands (glucan, arabinomannan, mannan), CR3-modulating lipids (phthiocerol dimycocerosate), or proteins in the capsule of the Δrv0180c::km mutant in comparison to the wild-type or complemented strains. By contrast, we established that Rv0180c contributes to the functionality of the bacterial cell envelope regarding resistance to toxic molecule attack and cell shape. This alteration of bacterial shape could impair the engagement of membrane receptors that M. tuberculosis uses to invade host cells, and open a new perspective on the modulation of bacterial infectivity.

Identifiants

pubmed: 34724002
doi: 10.1371/journal.ppat.1010020
pii: PPATHOGENS-D-21-00671
pmc: PMC8584747
doi:

Substances chimiques

Bacterial Proteins 0
Polysaccharides 0
Virulence Factors 0
Matrix Metalloproteinases EC 3.4.24.-
Rv0198c protein, Mycobacterium tuberculosis EC 3.4.24.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010020

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Mol Microbiol. 2001 Jul;41(1):179-87
pubmed: 11454210
Am J Respir Crit Care Med. 2017 Jun 1;195(11):1519-1527
pubmed: 27997216
Chembiochem. 2015 Apr 13;16(6):977-89
pubmed: 25766777
PLoS Pathog. 2012 Sep;8(9):e1002946
pubmed: 23028335
Tuberculosis (Edinb). 2012 Mar;92(2):160-5
pubmed: 22197183
J Cell Biol. 2017 Mar 6;216(3):583-594
pubmed: 28242744
PLoS Pathog. 2012;8(3):e1002621
pubmed: 22479184
PLoS One. 2017 Oct 5;12(10):e0185656
pubmed: 28982116
Microbes Infect. 2000 Mar;2(3):289-94
pubmed: 10758405
Tuberculosis (Edinb). 2006 Sep;86(5):357-62
pubmed: 16360339
J Biol Chem. 2012 Jan 27;287(5):3337-48
pubmed: 22158618
J Bacteriol. 2009 Jan;191(2):625-31
pubmed: 19011036
Microbiology (Reading). 1995 Jul;141 ( Pt 7):1609-20
pubmed: 7551029
PLoS Comput Biol. 2015 Oct 08;11(10):e1004401
pubmed: 26447887
Nat Rev Microbiol. 2020 Jan;18(1):47-59
pubmed: 31728063
Immunol Res. 2002;25(3):219-27
pubmed: 12018461
PLoS Pathog. 2016 Jan 11;12(1):e1005351
pubmed: 26751071
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12989-94
pubmed: 14569030
J Infect Dis. 2015 May 1;211(9):1367-72
pubmed: 25387581
PLoS Pathog. 2009 Feb;5(2):e1000289
pubmed: 19197369
PLoS One. 2011;6(9):e25075
pubmed: 21949856
Biochemistry. 2013 Apr 30;52(17):2895-904
pubmed: 23560677
Nature. 1991 Jun 6;351(6326):456-60
pubmed: 1904554
Cell. 2013 Dec 5;155(6):1296-308
pubmed: 24315099
Nature. 2001 Jul 12;412(6843):190-4
pubmed: 11449276
Trends Microbiol. 2017 Aug;25(8):688-697
pubmed: 28366292
Biochem J. 2004 Mar 1;378(Pt 2):589-97
pubmed: 14627436
Nature. 2001 Feb 22;409(6823):1007-11
pubmed: 11234002
Infect Immun. 2009 Oct;77(10):4538-47
pubmed: 19651855
J Cell Biol. 1993 Feb;120(4):1031-43
pubmed: 7679388
J Mol Biol. 2008 Aug 1;381(1):129-40
pubmed: 18597781
Methods Mol Biol. 2008;435:203-15
pubmed: 18370078
Microbiol Spectr. 2014 Aug;2(4):MGM2-0021-2013
pubmed: 26104202
Mol Cell. 2000 Apr;5(4):717-27
pubmed: 10882107
J Bacteriol. 1996 Jan;178(2):456-61
pubmed: 8550466
PLoS One. 2012;7(8):e43012
pubmed: 22900082
J Biol Chem. 2001 Jun 8;276(23):19845-54
pubmed: 11279114
PLoS Pathog. 2019 Mar 6;15(3):e1007613
pubmed: 30840702
Peptides. 2011 Jan;32(1):1-10
pubmed: 20883740
PLoS Pathog. 2010 Mar 05;6(3):e1000794
pubmed: 20221442
Cell Host Microbe. 2021 Jan 13;29(1):68-82.e5
pubmed: 33142108
Mol Microbiol. 2012 Jun;84(5):874-91
pubmed: 22548341
Nature. 1998 Jun 11;393(6685):537-44
pubmed: 9634230
Infect Immun. 1996 Dec;64(12):5373-83
pubmed: 8945590
Nat Med. 2019 Feb;25(2):255-262
pubmed: 30664782
PLoS Pathog. 2011 Sep;7(9):e1002251
pubmed: 21980284
Infect Immun. 1997 Oct;65(10):4258-66
pubmed: 9317035
J Bacteriol. 2001 Apr;183(7):2157-64
pubmed: 11244052
Infect Immun. 1999 Feb;67(2):469-77
pubmed: 9916047
EMBO J. 2006 Apr 5;25(7):1436-44
pubmed: 16541102
Curr Opin Cell Biol. 2020 Oct;66:112-122
pubmed: 32698097
PLoS Pathog. 2016 Aug 11;12(8):e1005768
pubmed: 27513637
ACS Chem Biol. 2016 Oct 21;11(10):2865-2875
pubmed: 27548027
Nat Rev Microbiol. 2013 Jul;11(7):435-42
pubmed: 23712350
Nat Cell Biol. 2019 Nov;21(11):1357-1369
pubmed: 31659275
Nature. 2008 Aug 7;454(7205):717-21
pubmed: 18685700
Curr Top Microbiol Immunol. 1996;215:71-96
pubmed: 8791710
Int J Tuberc Lung Dis. 2018 Aug 1;22(8):863-870
pubmed: 29991394
Int J Biol Macromol. 2020 Oct 15;161:712-720
pubmed: 32522539
Infect Immun. 1998 Apr;66(4):1277-81
pubmed: 9529042
Semin Immunol. 2014 Dec;26(6):471-85
pubmed: 25453226
Am J Epidemiol. 1995 Jul 1;142(1):3-14
pubmed: 7785671
Microbiology (Reading). 1996 Jun;142 ( Pt 6):1513-1520
pubmed: 8704991
Bioinformatics. 2020 May 1;36(10):3148-3155
pubmed: 32096818
Sci Adv. 2020 Sep 16;6(38):
pubmed: 32938674
Microbiol Mol Biol Rev. 2016 Feb 10;80(1):187-203
pubmed: 26864431
Immunol Cell Biol. 2014 Sep;92(8):699-708
pubmed: 24890643
Cell Host Microbe. 2018 Sep 12;24(3):439-446.e4
pubmed: 30146391
Mol Microbiol. 2006 Apr;60(2):312-30
pubmed: 16573683

Auteurs

Delphine Payros (D)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Henar Alonso (H)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Wladimir Malaga (W)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Arnaud Volle (A)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Serge Mazères (S)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Sébastien Déjean (S)

Institut de Mathématiques de Toulouse, UMR5219, Université de Toulouse, CNRS, UPS, Toulouse, France.

Sophie Valière (S)

INRAE, GeT-PlaGe, Genotoul, Castanet-Tolosan, France.

Flavie Moreau (F)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Stéphanie Balor (S)

Plateforme de Microscopie Électronique Intégrative (METi), Centre de Biologie Intégrative (CBI), CNRS, Toulouse, France.

Alexandre Stella (A)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Lucie Combes-Soia (L)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Odile Burlet-Schiltz (O)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Olivier Bouchez (O)

INRAE, GeT-PlaGe, Genotoul, Castanet-Tolosan, France.

Jérôme Nigou (J)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Catherine Astarie-Dequeker (C)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Christophe Guilhot (C)

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH